Firstline Daratumumab Shows High Hematologic and Organ Response Rates in Advanced Cardiac AL Amyloidosis - a Retrospective Case Series

被引：1
|
作者：
Jeryczynski, Georg [1 ]
Eder, Antonia [2 ]
Reitter, Eva-Maria [1 ]
Krauth, Maria-Theresa [3 ]
Agis, Hermine [1 ]
机构：
[1] Med Univ Vienna, Div Oncol, Dept Internal Med 1, Vienna, Austria
[2] Med Univ Vienna, Div Hematol & Hemostaseol, Dept Internal Med 1, Vienna, Austria
[3] Med Univ Vienna, Div Hematol & Hemostaseol, Dept Med 1, Vienna, Austria
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-124681
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3123
引用
收藏
页数：3
相关论文
共 8 条
  • [1] Hematologic Responses and Cardiac Organ Improvement in Patients with Heavily Pretreated Cardiac Immunoglobulin Light Chain (AL) Amyloidosis Receiving Daratumumab
    Kaufman, Gregory
    Witteles, Ronald
    Wheeler, Matthew
    Ulloa, Patricia
    Lugtu, Marie
    Arai, Sally
    Schrier, Stanley
    Lafayette, Richard
    Liedtke, Michaela
    BLOOD, 2016, 128 (22)
  • [2] Rapid organ response in a case of advanced cardiac AL amyloidosis by single-agent ixazomib
    Ihne, S. M.
    Morbach, C.
    Geier, A.
    Zeller, D.
    Sommer, C.
    Frantz, S.
    Stoerk, S.
    Einsele, H.
    Knop, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 191 - 191
  • [3] AL CARDIAC AMYLOIDOSIS WITH MULTIPLE CARDIAC MASSES: A RARE CASE OF PROGRESSION OF DISEASE DESPITE HEMATOLOGIC RESPONSE
    Sharp, Madeline
    Rearick, Corey
    Nosenchuck, Clare M.
    Franz, Joseph
    Levenson, Joshua Eric
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 2845 - 2845
  • [4] Long-term response to daratumumab in a patient with advanced immunoglobulin light-chain (AL) amyloidosis with organ damage
    Canichella, Martina
    Serrao, Alessandra
    Annechini, Giorgia
    D'Elia, Gianna Maria
    De Luca, Maria Lucia
    Pulsoni, Alessandro
    ANNALS OF HEMATOLOGY, 2019, 98 (04) : 1047 - 1048
  • [5] Long-term response to daratumumab in a patient with advanced immunoglobulin light-chain (AL) amyloidosis with organ damage
    Martina Canichella
    Alessandra Serrao
    Giorgia Annechini
    Gianna Maria D’Elia
    Maria Lucia De Luca
    Alessandro Pulsoni
    Annals of Hematology, 2019, 98 : 1047 - 1048
  • [6] First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience
    Jeryczynski, G.
    Antlanger, M.
    Duca, F.
    Binder-Rodriguez, C.
    Reiter, T.
    Simonitsch-Klupp, I
    Bonderman, D.
    Kain, R.
    Krauth, M-T
    Agis, H.
    ESMO OPEN, 2021, 6 (02)
  • [7] Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) plus /- Daratumumab Treatment Results in Sustained Hematologic Response in Patients with AL Amyloidosis: A Retrospective Analysis of Patients at Mayo Clinic
    Kusne, Yael
    Fonseca, Rodrigo
    Arribas, Mariano
    Klanderman, Molly
    Wiedmeier, Julia E.
    Reeder, Craig B.
    Larsen, Jeremy T.
    Bergsagel, P. Leif
    Rosenthal, Julie L.
    Fonseca, Rafael
    BLOOD, 2022, 140 : 7224 - 7225
  • [8] Outcome of Patients with AL Amyloidosis Who Do Not Achieve Hematologic Complete Response After Treatment with High Dose Melphalan and Autologous Transplantation: Results In a Series of 421 Patients
    Teresa Cibeira, M.
    Sanchorawala, Vaishali
    Seldin, David C.
    Quillen, Karen
    Andrea, Nancy
    Sloan, J. Mark
    Finn, Kathleen T.
    Berk, John L.
    Doros, Gheorghe
    Blade, Joan
    Skinner, Martha
    BLOOD, 2010, 116 (21) : 992 - 992
1